Insulin glargine (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Insulin glargine" in English language version.

refsWebsite

Global rank English rank

17web.archive.org

1^st place

12nih.gov

4^th place

8doi.org

2^nd place

8europa.eu

68^th place

117^th place

2drugs.com

399^th place

333^rd place

2clincalc.com

3,912^th place

2,496^th place

2fda.gov

447^th place

338^th place

1hres.ca

low place

1medicines.org.uk

3,823^rd place

2,387^th place

1handle.net

102^nd place

76^th place

1harvard.edu

18^th place

17^th place

1semanticscholar.org

11^th place

8^th place

1sanofi.us

low place

1patents.google.com

1,182^nd place

725^th place

clincalc.com

"The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.
"Insulin Glargine - Drug Usage Statistics". ClinCalc. Retrieved 14 January 2024.

doi.org

Hemmingsen B, Metzendorf MI, Richter B (March 2021). "(Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus". The Cochrane Database of Systematic Reviews. 3 (4): CD013498. doi:10.1002/14651858.cd013498.pub2. PMC 8094220. PMID 33662147.
Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S (July 2010). "Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation". Health Technology Assessment. 14 (36): 1–248. doi:10.3310/hta14360. PMID 20646668.
Singh SR, Ahmad F, Lal A, Yu C, Bai Z, Bennett H (February 2009). "Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis". CMAJ. 180 (4): 385–397. doi:10.1503/cmaj.081041. PMC 2638025. PMID 19221352.
American Diabetes Association (January 2003). "Insulin administration". Diabetes Care. 26 (Suppl. 1): S121–S124. doi:10.2337/diacare.26.2007.S121. PMID 12502637.
Kaplan W, Rodriguez LM, Smith OE, Haymond MW, Heptulla RA (November 2004). "Effects of mixing glargine and short-acting insulin analogs on glucose control". Diabetes Care. 27 (11): 2739–2740. doi:10.2337/diacare.27.11.2739. PMID 15505016.
Tang X, Yang L, He Z, Liu J (2012). "Insulin glargine and cancer risk in patients with diabetes: a meta-analysis". PLOS ONE. 7 (12): e51814. Bibcode:2012PLoSO...751814T. doi:10.1371/journal.pone.0051814. PMC 3526637. PMID 23284776.
Rendell M, Akturk HK, Tella SH (March 2013). "Glargine safety, diabetes and cancer". Expert Opinion on Drug Safety. 12 (2): 247–263. doi:10.1517/14740338.2013.770469. PMID 23394441. S2CID 9224923.
Bolli GB, Di Marchi RD, Park GD, Pramming S, Koivisto VA (October 1999). "Insulin analogues and their potential in the management of diabetes mellitus". Diabetologia. 42 (10): 1151–1167. doi:10.1007/s001250051286. PMID 10525654.

drugs.com

"Insulin glargine Use During Pregnancy". Drugs.com. 6 April 2020. Archived from the original on 21 October 2020. Retrieved 4 September 2020.
"Insulin Glargine Monograph for Professionals". Drugs.com. AHFS. Archived from the original on 5 December 2020. Retrieved 23 December 2018.

europa.eu

ema.europa.eu

"Lantus EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 4 August 2020. Retrieved 28 July 2021.
"Toujeo EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 29 July 2021. Retrieved 28 July 2021.
"Lantus EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 4 August 2020. Retrieved 7 May 2020.
"Abasaglar EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 2 April 2022. Retrieved 28 July 2021.
"Lusduna EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 29 July 2021. Retrieved 28 July 2021.
"Semglee EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 15 February 2022. Retrieved 28 July 2021.

emea.europa.eu

EPAR Lantus Archived 22 November 2006 at the Wayback Machine, German summary of admission report of the European Medicines Agency (PDF)

ec.europa.eu

"Abasaglar Product information". Union Register of medicinal products. 11 September 2014. Retrieved 1 October 2023.

fda.gov

"FDA Approves First Interchangeable Biosimilar Insulin Product for Treatment of Diabetes". U.S. Food and Drug Administration (FDA) (Press release). 28 July 2021. Archived from the original on 28 August 2021. Retrieved 28 July 2021. This article incorporates text from this source, which is in the public domain.

accessdata.fda.gov

"Toujeo: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Archived from the original on 14 August 2020. Retrieved 7 May 2020.

handle.net

hdl.handle.net

World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.

harvard.edu

ui.adsabs.harvard.edu

Tang X, Yang L, He Z, Liu J (2012). "Insulin glargine and cancer risk in patients with diabetes: a meta-analysis". PLOS ONE. 7 (12): e51814. Bibcode:2012PLoSO...751814T. doi:10.1371/journal.pone.0051814. PMC 3526637. PMID 23284776.

hres.ca

hpr-rps.hres.ca

"Summary Basis of Decision - Semglee". Health Canada. 23 August 2022. Archived from the original on 29 September 2022. Retrieved 29 September 2022.

medicines.org.uk

"Lantus 100 units/ml solution for injection in a cartridge - Summary of Product Characteristics (SmPC)". (emc). Archived from the original on 9 January 2021. Retrieved 7 May 2020.

nih.gov

pubmed.ncbi.nlm.nih.gov

Hemmingsen B, Metzendorf MI, Richter B (March 2021). "(Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus". The Cochrane Database of Systematic Reviews. 3 (4): CD013498. doi:10.1002/14651858.cd013498.pub2. PMC 8094220. PMID 33662147.
Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S (July 2010). "Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation". Health Technology Assessment. 14 (36): 1–248. doi:10.3310/hta14360. PMID 20646668.
Singh SR, Ahmad F, Lal A, Yu C, Bai Z, Bennett H (February 2009). "Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis". CMAJ. 180 (4): 385–397. doi:10.1503/cmaj.081041. PMC 2638025. PMID 19221352.
American Diabetes Association (January 2003). "Insulin administration". Diabetes Care. 26 (Suppl. 1): S121–S124. doi:10.2337/diacare.26.2007.S121. PMID 12502637.
Kaplan W, Rodriguez LM, Smith OE, Haymond MW, Heptulla RA (November 2004). "Effects of mixing glargine and short-acting insulin analogs on glucose control". Diabetes Care. 27 (11): 2739–2740. doi:10.2337/diacare.27.11.2739. PMID 15505016.
Tang X, Yang L, He Z, Liu J (2012). "Insulin glargine and cancer risk in patients with diabetes: a meta-analysis". PLOS ONE. 7 (12): e51814. Bibcode:2012PLoSO...751814T. doi:10.1371/journal.pone.0051814. PMC 3526637. PMID 23284776.
Rendell M, Akturk HK, Tella SH (March 2013). "Glargine safety, diabetes and cancer". Expert Opinion on Drug Safety. 12 (2): 247–263. doi:10.1517/14740338.2013.770469. PMID 23394441. S2CID 9224923.
Bolli GB, Di Marchi RD, Park GD, Pramming S, Koivisto VA (October 1999). "Insulin analogues and their potential in the management of diabetes mellitus". Diabetologia. 42 (10): 1151–1167. doi:10.1007/s001250051286. PMID 10525654.

ncbi.nlm.nih.gov

Hemmingsen B, Metzendorf MI, Richter B (March 2021). "(Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus". The Cochrane Database of Systematic Reviews. 3 (4): CD013498. doi:10.1002/14651858.cd013498.pub2. PMC 8094220. PMID 33662147.
Singh SR, Ahmad F, Lal A, Yu C, Bai Z, Bennett H (February 2009). "Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis". CMAJ. 180 (4): 385–397. doi:10.1503/cmaj.081041. PMC 2638025. PMID 19221352.
Tang X, Yang L, He Z, Liu J (2012). "Insulin glargine and cancer risk in patients with diabetes: a meta-analysis". PLOS ONE. 7 (12): e51814. Bibcode:2012PLoSO...751814T. doi:10.1371/journal.pone.0051814. PMC 3526637. PMID 23284776.

dailymed.nlm.nih.gov

"Lantus- insulin glargine injection, solution Lantus SoloStar- insulin glargine injection, solution". DailyMed. Archived from the original on 29 July 2021. Retrieved 29 July 2021.

patents.google.com

"Amidated insulin glargine". Archived from the original on 29 September 2022. Retrieved 17 August 2020.

sanofi.us

news.sanofi.us

"Sanofi Receives FDA Approval of Once-Daily Basal Insulin Toujeo" (Press release). Sanofi. 25 February 2015. Archived from the original on 27 February 2015.

semanticscholar.org

api.semanticscholar.org

Rendell M, Akturk HK, Tella SH (March 2013). "Glargine safety, diabetes and cancer". Expert Opinion on Drug Safety. 12 (2): 247–263. doi:10.1517/14740338.2013.770469. PMID 23394441. S2CID 9224923.

web.archive.org

"Insulin glargine Use During Pregnancy". Drugs.com. 6 April 2020. Archived from the original on 21 October 2020. Retrieved 4 September 2020.
"Summary Basis of Decision - Semglee". Health Canada. 23 August 2022. Archived from the original on 29 September 2022. Retrieved 29 September 2022.
"Lantus 100 units/ml solution for injection in a cartridge - Summary of Product Characteristics (SmPC)". (emc). Archived from the original on 9 January 2021. Retrieved 7 May 2020.
"Lantus- insulin glargine injection, solution Lantus SoloStar- insulin glargine injection, solution". DailyMed. Archived from the original on 29 July 2021. Retrieved 29 July 2021.
"Lantus EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 4 August 2020. Retrieved 28 July 2021.
"Toujeo EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 29 July 2021. Retrieved 28 July 2021.
"Insulin Glargine Monograph for Professionals". Drugs.com. AHFS. Archived from the original on 5 December 2020. Retrieved 23 December 2018.
"The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.
"FDA Approves First Interchangeable Biosimilar Insulin Product for Treatment of Diabetes". U.S. Food and Drug Administration (FDA) (Press release). 28 July 2021. Archived from the original on 28 August 2021. Retrieved 28 July 2021. This article incorporates text from this source, which is in the public domain.
"Lantus EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 4 August 2020. Retrieved 7 May 2020.
EPAR Lantus Archived 22 November 2006 at the Wayback Machine, German summary of admission report of the European Medicines Agency (PDF)
"Sanofi Receives FDA Approval of Once-Daily Basal Insulin Toujeo" (Press release). Sanofi. 25 February 2015. Archived from the original on 27 February 2015.
"Toujeo: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Archived from the original on 14 August 2020. Retrieved 7 May 2020.
"Abasaglar EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 2 April 2022. Retrieved 28 July 2021.
"Lusduna EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 29 July 2021. Retrieved 28 July 2021.
"Semglee EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 15 February 2022. Retrieved 28 July 2021.
"Amidated insulin glargine". Archived from the original on 29 September 2022. Retrieved 17 August 2020.